CN110772517B - 波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 - Google Patents
波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 Download PDFInfo
- Publication number
- CN110772517B CN110772517B CN201911213975.1A CN201911213975A CN110772517B CN 110772517 B CN110772517 B CN 110772517B CN 201911213975 A CN201911213975 A CN 201911213975A CN 110772517 B CN110772517 B CN 110772517B
- Authority
- CN
- China
- Prior art keywords
- uric acid
- boldine
- salt
- level
- nephropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LZJRNLRASBVRRX-ZDUSSCGKSA-N Boldine Chemical compound CN1CCC2=CC(O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-ZDUSSCGKSA-N 0.000 title claims abstract description 63
- LZJRNLRASBVRRX-UHFFFAOYSA-N boldine trifluoroacetic acid salt Natural products CN1CCC2=CC(O)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-UHFFFAOYSA-N 0.000 title claims abstract description 32
- KYVJVURXKAZJRK-UHFFFAOYSA-N (+)-laurolitsine Natural products N1CCC2=CC(O)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 KYVJVURXKAZJRK-UHFFFAOYSA-N 0.000 title claims abstract description 31
- MHVCSDLBQKSFQV-HNNXBMFYSA-N boldine Natural products COc1cc2c(C[C@@H]3N(C)CCc4cc(C)c(OC)c2c34)cc1O MHVCSDLBQKSFQV-HNNXBMFYSA-N 0.000 title claims abstract description 31
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 150000003839 salts Chemical class 0.000 title claims abstract description 20
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 19
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229940116269 uric acid Drugs 0.000 title claims abstract description 18
- 210000004369 blood Anatomy 0.000 title claims abstract description 14
- 239000008280 blood Substances 0.000 title claims abstract description 14
- 206010046337 Urate nephropathy Diseases 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 14
- 208000017169 kidney disease Diseases 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000017074 necrotic cell death Effects 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 210000005239 tubule Anatomy 0.000 abstract description 4
- 201000002793 renal fibrosis Diseases 0.000 abstract description 3
- 239000002547 new drug Substances 0.000 abstract description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 8
- 229940109239 creatinine Drugs 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 5
- 229960003459 allopurinol Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229950000193 oteracil Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002248 lipoperoxidative effect Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途，属于医药领域。一方面，本发明提供了波尔定碱或其盐在制备降低血尿酸水平的药品或保健品中的用途。另一方面，本发明还提供了波尔定碱或其盐在制备预防和/或治疗尿酸性肾病的药品中的用途。动物实验证明，波尔定碱能够大幅降低血尿酸水平，同时改善高尿酸血症小鼠肾小管扩张、坏死以及肾纤维化的程度。本发明的应用能够为临床治疗高尿酸血症及其导致的高尿酸肾病提供新的用药选择。
Description
技术领域
本发明涉及波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途，属于医药领域。
背景技术
高尿酸血症指正常嘌呤饮食情况下，非同日两次测定空腹血清尿酸水平男性≥416μmol/L(7mg/dl)，女性≥357μmol/L(6mg/dl)。近年来，国内外众多研究证实高尿酸血症与痛风、心血管疾病、代谢综合征、高血压及肾脏疾病的发生发展密切相关。高尿酸血症是慢性肾脏病(Chronic Kidney Disease，CKD)患病率增高的重要原因，并且是CKD进展的独立风险因素。研究表明，降低血尿酸水平可以延缓肾脏疾病进展。治疗高尿酸肾病重在预防、纠正高尿酸血症，降低血尿酸水平，防止尿酸盐沉积在肾脏。
波尔定碱(Boldine)，化学名称2,9-二羟基-1,10-二甲氧基阿朴啡，其结构式如下所示：
现有研究表明，波尔定碱可以抑制体外低密度脂蛋白的氧化和体内动脉粥样硬化，预防人类肝脏微粒体的脂肪过氧化和细胞色素P4502E1的失活，阻止因为线粒体的氧化而造成的一些疾病(参见：Santanam N,Penumetcha M,Speisky H,et al.A novelalkaloid antioxidant,boldine and synthetic antioxidant,reduced form of RU486,inhibit the oxidation of LDL in-vitro and atherosclerosis in vivo in LDLR-/(-)mice[J].Atherosclerosis,2004,173(2):203-210.)。另外，波尔定碱还是一种在一些地区被广泛应用的抗癌药物。
然而，迄今尚未见波尔定碱具有降尿酸、防治尿酸性肾病作用的相关报道。
发明内容
本发明旨在至少解决现有技术中存在的技术问题之一。为此，本发明的目的在于提供波尔定碱或其盐在制备降低血尿酸水平的药品或保健品中的用途。本发明的另一目的在于提供波尔定碱或其盐在制备预防和/或治疗尿酸性肾病的药品中的用途。
本发明提供了波尔定碱或其盐在制备降低血尿酸水平的药品或保健品中的用途。
本发明提供了波尔定碱或其盐在制备预防和/或治疗尿酸性肾病的药品中的用途。
进一步地，所述的药品降低血肌酐水平。
进一步地，所述的药品降低血尿酸水平。
进一步地，所述的药品降低尿蛋白肌酐比。
进一步地，所述的药品改善肾小管扩张和/或坏死。
进一步地，所述的药品减少肾脏炎性细胞数量。
进一步地，所述的药品改善肾纤维化。
进一步地，所述的药品或保健品是以波尔定碱或其盐为活性成分，加入可接受的辅料或者辅助性成分制备而成的制剂。
进一步地，所述的制剂为口服制剂或注射制剂。
本发明中，波尔定碱的盐是指波尔定碱与无机酸和/或碱、有机酸和/或碱形成的酸式和/或碱式盐，也包括两性离子盐(内盐)，还包括季铵盐，例如烷基铵盐。本发明所述的盐例如可以是波尔定碱的盐酸盐、硫酸盐、枸橼酸盐、苯磺酸盐、氢溴酸盐、氢氟酸盐、磷酸盐、乙酸盐、丙酸盐、丁二酸盐、草酸盐、苹果酸盐、琥珀酸盐、富马酸盐、马来酸盐、酒石酸盐或三氟乙酸盐。
本发明提供了波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途。动物实验证明，波尔定碱能够大幅降低血尿酸水平，同时改善高尿酸血症小鼠肾小管扩张、坏死以及肾纤维化的程度。本发明的应用能够为临床治疗高尿酸血症及其导致的高尿酸肾病提供新的用药选择。
附图说明
图1为实施例1中小鼠血尿酸水平检测结果图；
图2为实施例1中小鼠血肌酐水平检测结果图；
图3为实施例1中小鼠尿蛋白肌酐比检测结果图；
图4为实施例1中小鼠肾脏组织PAS染色图；
图5为实施例1中小鼠肾脏MASSON染色图。
具体实施方式
下面将结合实施例对本发明的方案进行解释。本领域技术人员将会理解，下面的实施例仅用于说明本发明，而不应视为限定本发明的范围。实施例中未注明具体技术或条件的，按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购获得的常规产品。
实施例1波尔定碱降低血尿酸水平及防治尿酸性肾病的作用
实验动物：SPF级雄性C57BL/6J小鼠。实验前至少1周恒温环境下标准化实验日粮饲养，饮水不限。
动物分组：将小鼠48只分为4组：①正常对照组12只；②高尿酸肾病模型组12只；③波尔定碱治疗组(30mg/kg/d)12只；阳性对照别嘌呤醇(5mg/kg/d)12只。
造模方法：根据小鼠体质量以腺嘌呤100mg/kg、氧嗪酸钾1500mg/kg的比例，用蒸馏水将两者混合后制成终浓度为80g/L的混悬液，模型组每日早晚灌胃，连续3周，建立高尿酸血症肾损害动物模型。正常对照组动物每日早晚两次等剂量的蒸馏水灌胃。3周后处死小鼠，腹主动脉取血，留取肾脏组织。
实验方法：波尔定碱和别嘌呤醇治疗组于造模后第1天开始采用口服给药方式给药，连续21天；模型组造模后在相同时间灌喂同等剂量生理盐水；正常对照组在相同时间灌喂同等剂量生理盐水。
小鼠血液样本在室温3000r/min离心15min后取血清测定生化指标；小鼠尿液标本在室温800g/min离心10min后取上层尿液测定生化指标。实验结果见图1～图3。对小鼠肾脏组织进行PAS染色，观察肾脏结构，实验结果见图4。采用MASSON染色观测肾脏纤维化情况，实验结果见图5。
从图1可以看出，波尔定碱能够大幅降低血尿酸水平，且效果与降尿酸临床一线用药别嘌呤醇相当。
从图2可以看出，波尔定碱降低血肌酐水平，效果甚至优于别嘌呤醇，具有改善肾功能的作用。
从图3可以看出，波尔定碱降低尿蛋白肌酐比，效果明显优于别嘌呤醇，具有改善肾功能的作用。
从图4可以看出，正常对照组小鼠肾脏的PAS染色图片具有完整的肾脏结构，没有明显的肾小管变性、坏死，管状萎缩，没有炎性细胞浸润和纤维化。高尿酸肾脏病模型组在第21天时可见肾小管有明显的扩张，小管坏死和核脱落及间质炎性细胞侵入。使用波尔定碱30mg/kg/d治疗21天后明显改善肾小管扩张和坏死，减轻肾脏炎性细胞数量。
从图5可以看出，正常对照组肾脏的MASSON染色图片具有完整的肾脏结构，没有明显的肾小管变性、坏死，管状萎缩，没有炎性细胞浸润和纤维化。高尿酸肾脏病模型组在第21天时可见肾小管有明显的扩张，MASSON染色蓝色区域明显(蓝色区域表示纤维化病变的程度)。使用波尔定碱30mg/kg/d治疗21天后，MASSON染色蓝色区域明显少于高尿酸肾脏病模型组。
Claims (4)
1.波尔定碱或其盐在制备降低血尿酸水平的药品中的用途。
2.波尔定碱或其盐在制备预防和/或治疗尿酸性肾病的药品中的用途。
3.如权利要求1或2所述的用途，其特征是：所述的药品是以波尔定碱或其盐为活性成分，加入可接受的辅料制备而成的制剂。
4.如权利要求3所述的用途，其特征是：所述的制剂为口服制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911213975.1A CN110772517B (zh) | 2019-12-02 | 2019-12-02 | 波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911213975.1A CN110772517B (zh) | 2019-12-02 | 2019-12-02 | 波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110772517A CN110772517A (zh) | 2020-02-11 |
| CN110772517B true CN110772517B (zh) | 2022-10-04 |
Family
ID=69393497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911213975.1A Active CN110772517B (zh) | 2019-12-02 | 2019-12-02 | 波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110772517B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118251379A (zh) * | 2021-11-15 | 2024-06-25 | 学校法人自治医科大学 | 铁死亡抑制剂及其用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004307352A (ja) * | 2003-04-02 | 2004-11-04 | Croda Japan Kk | ボルジン誘導体を含有する化粧料または皮膚外用剤 |
| CN105732499A (zh) * | 2014-12-11 | 2016-07-06 | 上海壹志医药科技有限公司 | 异波尔定碱衍生物的药物用途 |
| CN108785312A (zh) * | 2018-07-09 | 2018-11-13 | 武汉轻工大学 | 一种急性高尿酸血症肾损害小鼠模型的构建方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140023653A1 (en) * | 2012-07-16 | 2014-01-23 | Osteogenex, Inc. | Boldine derivatives for promoting bone growth |
-
2019
- 2019-12-02 CN CN201911213975.1A patent/CN110772517B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004307352A (ja) * | 2003-04-02 | 2004-11-04 | Croda Japan Kk | ボルジン誘導体を含有する化粧料または皮膚外用剤 |
| CN105732499A (zh) * | 2014-12-11 | 2016-07-06 | 上海壹志医药科技有限公司 | 异波尔定碱衍生物的药物用途 |
| CN108785312A (zh) * | 2018-07-09 | 2018-11-13 | 武汉轻工大学 | 一种急性高尿酸血症肾损害小鼠模型的构建方法 |
Non-Patent Citations (5)
| Title |
|---|
| a novel alkaloid antioxidant, boldine and synthetic antioxidant, reduced form of ru486, inhibit the oxidation of ldl in-vitro and atherosclerosis in vivo in ldlr mice;N. Santanam等;《Atherosclerosis》;20041231;第203-210页 * |
| Boldine Improves Kidney Damage in the Goldblatt 2K1C Model Avoiding the Increase in TGF-β;Gonzalo I. Gómez等;《International Journal of Molecular Science》;20180625;第1-17页 * |
| Natural Aporphine Alkaloids with Potential to Impact Metabolic Syndrome;Fei-Xuan Wang等;《molecules》;20211010;第1-22页 * |
| The role of resistin on metabolic syndrome‐induced erectile dysfunction and the possible therapeutic effect of Boldine;Erkan Kara等;《Andrology》;20201231;第1728-1735页 * |
| 紫檀芪对高尿酸血症及尿酸性肾脏纤维化改善作用及其机制研究;潘静等;《中国中西医结合学会肾脏疾病专业委员会2018年学术年会论文摘要汇编》;20181011;第PO-571页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110772517A (zh) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7767225B2 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
| TWI290051B (en) | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole | |
| CN111918646B (zh) | 延迟释放去铁酮片剂及其使用方法 | |
| CN107427502A (zh) | 使用川地匹坦的治疗方法 | |
| WO2007072911A1 (ja) | 塩酸サプロプテリンの生体内吸収性を向上させた製剤 | |
| CN110772517B (zh) | 波尔定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 | |
| CN110772516B (zh) | 异紫堇定碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 | |
| JP2006524190A (ja) | 薬剤のメントール溶液 | |
| KR20090086686A (ko) | 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법 | |
| JPH1053520A (ja) | 抗疲労剤 | |
| CN111728974A (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| AU2017328975B2 (en) | Sublingual or buccal administration of dim for treatment of skin diseases | |
| US20050101605A1 (en) | Oral liquid formulations of methotrexate | |
| EP4180040A2 (en) | Pharmaceutical composition and application thereof | |
| AU2016301689B2 (en) | Ameliorating agent for detrusor hyperactivity with impaired contractility | |
| CN110772519A (zh) | 青藤碱或其盐在制备降低血尿酸水平、防治尿酸性肾病的药品中的用途 | |
| CN112755018A (zh) | 漆黄素在制备防治尿酸性肾病的药物中的用途 | |
| US6197818B1 (en) | Drug for treating diabetic nephrosis | |
| CN113413365B (zh) | 一种稳定的法维拉韦口服溶液制剂及其制备方法 | |
| EP3981423B1 (en) | Composition for preventing or treating uric acid-related disease | |
| CN112516121B (zh) | 包含牛磺酸和别嘌醇的组合物及其医药用途 | |
| JPH0717853A (ja) | 高脂血症治療剤 | |
| CN115243774B (zh) | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 | |
| US20240245666A1 (en) | Dosing regimens | |
| CN100560075C (zh) | 调节脂类代谢的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |